KR20120059520A - 이상지질혈증을 치료하기 위한 멜라노코르틴의 용도 - Google Patents

이상지질혈증을 치료하기 위한 멜라노코르틴의 용도 Download PDF

Info

Publication number
KR20120059520A
KR20120059520A KR1020127005642A KR20127005642A KR20120059520A KR 20120059520 A KR20120059520 A KR 20120059520A KR 1020127005642 A KR1020127005642 A KR 1020127005642A KR 20127005642 A KR20127005642 A KR 20127005642A KR 20120059520 A KR20120059520 A KR 20120059520A
Authority
KR
South Korea
Prior art keywords
arg
cys
ala
trp
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127005642A
Other languages
English (en)
Korean (ko)
Inventor
헤더 에이. 할렘
마이클 드윗 컬러
Original Assignee
입센 파마 에스.에이.에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 입센 파마 에스.에이.에스 filed Critical 입센 파마 에스.에이.에스
Publication of KR20120059520A publication Critical patent/KR20120059520A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020127005642A 2009-08-05 2010-07-30 이상지질혈증을 치료하기 위한 멜라노코르틴의 용도 Ceased KR20120059520A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27348809P 2009-08-05 2009-08-05
US61/273,488 2009-08-05
PCT/US2010/043832 WO2011017209A1 (en) 2009-08-05 2010-07-30 Use of melanocortins to treat dyslipidemia

Publications (1)

Publication Number Publication Date
KR20120059520A true KR20120059520A (ko) 2012-06-08

Family

ID=43544604

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127005642A Ceased KR20120059520A (ko) 2009-08-05 2010-07-30 이상지질혈증을 치료하기 위한 멜라노코르틴의 용도

Country Status (12)

Country Link
US (2) US20120135923A1 (cg-RX-API-DMAC7.html)
EP (1) EP2461681A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013501053A (cg-RX-API-DMAC7.html)
KR (1) KR20120059520A (cg-RX-API-DMAC7.html)
CN (1) CN102548399A (cg-RX-API-DMAC7.html)
AU (1) AU2010279719A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012002445A2 (cg-RX-API-DMAC7.html)
CA (1) CA2769883A1 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN01493A (cg-RX-API-DMAC7.html)
MX (1) MX2012001513A (cg-RX-API-DMAC7.html)
RU (1) RU2012108110A (cg-RX-API-DMAC7.html)
WO (1) WO2011017209A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2453328C2 (ru) 2007-11-05 2012-06-20 Ипсен Фарма С.А.С. Применение меланокортинов для лечения чувствительности к инсулину
US20120226018A1 (en) * 2009-11-16 2012-09-06 Ipsen Pharma, S.A.S. Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
EP2720684B1 (en) * 2011-06-14 2019-01-16 Ipsen Pharma S.A.S. A sustained-release composition containing peptides as the active ingredient
PT3539551T (pt) * 2011-12-29 2021-11-04 Rhythm Pharmaceuticals Inc Método de tratamento de distúrbios associados ao recetor de melanocortina-4 em portadores heterozigóticos
RU2020120797A (ru) 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
CA3209602A1 (en) 2013-03-15 2014-09-18 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
AU2016330773A1 (en) 2015-09-30 2018-04-19 Charité-Universitätsmedizin Berlin Method of treating melanocortin-4 receptor pathway-associated disorders
US20210221867A1 (en) * 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1635813A4 (en) * 2003-06-06 2009-07-01 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
WO2006048451A1 (en) * 2004-11-04 2006-05-11 Novo Nordisk A/S Peptides for use in the treatment of obesity
CN105837661B (zh) * 2005-07-08 2024-10-15 益普生制药股份有限公司 黑皮质素受体配体
CN101528250A (zh) * 2005-07-08 2009-09-09 研究及应用科学协会股份有限公司 黑皮质素受体的配体
EP2148692B1 (en) * 2007-05-25 2017-01-25 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
US20100173834A1 (en) * 2007-06-15 2010-07-08 Zheng Xin Dong Cyclic peptide melanocortin receptor ligands
RU2453328C2 (ru) * 2007-11-05 2012-06-20 Ипсен Фарма С.А.С. Применение меланокортинов для лечения чувствительности к инсулину

Also Published As

Publication number Publication date
CA2769883A1 (en) 2011-02-10
RU2012108110A (ru) 2013-09-10
EP2461681A4 (en) 2013-04-24
IN2012DN01493A (cg-RX-API-DMAC7.html) 2015-06-05
US20130331324A1 (en) 2013-12-12
WO2011017209A1 (en) 2011-02-10
CN102548399A (zh) 2012-07-04
EP2461681A1 (en) 2012-06-13
AU2010279719A1 (en) 2012-03-01
US20120135923A1 (en) 2012-05-31
JP2013501053A (ja) 2013-01-10
BR112012002445A2 (pt) 2015-10-13
MX2012001513A (es) 2012-05-22

Similar Documents

Publication Publication Date Title
KR101290623B1 (ko) 인슐린 민감성을 치료하기 위한 멜라노코르틴의 용도
RU2380372C2 (ru) Лиганды рецепторов меланокортинов
KR20120059520A (ko) 이상지질혈증을 치료하기 위한 멜라노코르틴의 용도
KR20080041639A (ko) 멜라노코르틴 수용체의 리간드
HK1221147B (en) Use of melanocortins to treat insulin sensitivity
HK1146242B (en) Use of melanocortins to treat insulin sensitivity

Legal Events

Date Code Title Description
A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000